Evidence map›Paper›PMID 32949412›Full record

Trial reportHematological oncology2021

Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.

Rui Cui, Cuicui Lyu, Qing Li, Yanyu Jiang, Nan Mou, Zhenxing Yang, Xuxiang Liu, Qi Deng, Lanfang Li

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Hematological oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Rui CuiDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.ORCID https://orcid.org/0000-0002-4994-5262
Cuicui LyuDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Qing LiDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Yanyu JiangDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Nan MouDepartment of Gene Therapy, Shanghai Genbase Biotechnology Co., Ltd, Shanghai, China.
Zhenxing YangDepartment of Gene Therapy, Shanghai Genbase Biotechnology Co., Ltd, Shanghai, China.
Xuxiang LiuDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Qi DengDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Lanfang LiDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Tianjin First Center Hospital · CNShanghai Genon Biological Products (China) · CNCity Of Hope National Medical Center · USTianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor-T (CAR-T) cell therapy is a promising treatment for CD19

Indexed as

Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveReceptors, Chimeric AntigenVirus ActivationAdultAllograftsFemaleHepatitis B, ChronicHepatitis B virusHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenHBV reactivationhumanized anti-CD19 CAR-Tleukemialymphomasafety

Identifiers

PMID32949412
PMCPMC7983916
OpenAlexW3087107688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.